HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

A Bretoni, L Ferrario, E Foglia - ClinicoEconomics and outcomes …, 2019 - Taylor & Francis
Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …
被引用次数：9 相关文章

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

A Bretoni, L Ferrario, E Foglia - ClinicoEconomics and Outcomes …, 2019 - dovepress.com
Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer.

A Bretoni, L Ferrario, E Foglia - Clinicoeconomics and Outcomes …, 2019 - europepmc.org
Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …
[HTML] nih.gov

[HTML][HTML] HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

A Bretoni, L Ferrario, E Foglia - ClinicoEconomics and Outcomes …, 2019 - ncbi.nlm.nih.gov
Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

A Bretoni, L Ferrario, E Foglia - … and outcomes research …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

A Bretoni, L Ferrario, E Foglia - ClinicoEconomics …, 2019 - liuc.esploro.exlibrisgroup.com
Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

A Bretoni, L Ferrario, E Foglia - … and Outcomes Research, 2019 - search.proquest.com
Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

A Bretoni, L Ferrario, E Foglia - ClinicoEconomics …, 2019 - liuc.esploro.exlibrisgroup.com
Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer.

A Bretoni, L Ferrario, E Foglia - Clinicoeconomics and Outcomes …, 2019 - europepmc.org
Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …